These outcomes will support a phase 2 clinical study of ALKS 37, that will assess the safety, tolerability and efficacy of ALKS 37 in people with OIC. The phase 2 study is expected to begin in the first fifty % of calendar 2010. SOURCE Alkermes, Inc.. Alkermes initiates multidose Stage 1 clinical research of ALKS 37 for OIC Alkermes, Inc. today announced the initiation of a multidose stage 1 clinical research of ALKS 37, an active orally, peripherally-restricted opioid antagonist with potential to block the consequences of opioid agonists on gastrointestinal motility, commonly known as opioid-induced constipation .More than one bout of atrial fibrillation occurred in 26.9 percent of the patients in the valsartan group, in comparison with 27.9 percent of the patients in the placebo group . After adjustment for all baseline variables reported in Desk 1, the adjusted chances ratio was 0.89 . Secondary Analyses and End Points Among the 1255 patients who were in sinus rhythm 15 times after study access, there is no significant difference between the valsartan and placebo groups with regards to the prices of recurrence of atrial fibrillation . Similar results were obtained from a post hoc evaluation of data from the 1254 individuals who were in sinus rhythm at week 8, by which time the patients would have been receiving the prospective dose of valsartan .